Question 1

What is the role of Complex I in the electron transport chain?

Accepted Answer

Complex I, or NADH-Q oxidoreductase, is the largest enzyme complex in the electron transport chain, containing 45 subunits. It transfers electrons from NADH to coenzyme Q through key catalytic components including an NADH-binding site, FMN as the primary electron acceptor, and multiple iron-sulfur clusters. This initiates the energetically downhill electron transfer sequence.

Question 2

How does Complex II differ from Complex I in structure and function?

Accepted Answer

Complex II, or succinate-Q reductase, is a nuclear-encoded tetramer with two hydrophilic subunits and two hydrophobic membrane proteins. Unlike Complex I, it participates in both the citric acid cycle and electron transport chain, transferring electrons from succinate through FADH2 to coenzyme Q via iron-sulfur clusters.

Question 3

What are the catalytic components of Complex I?

Accepted Answer

Complex I contains three major catalytic components: an NADH-binding site where high-energy electrons enter, FMN (flavin mononucleotide) as the primary electron acceptor, and multiple iron-sulfur clusters that facilitate electron transfer. These components work together to transfer electrons from NADH to coenzyme Q in a controlled, stepwise manner.

Question 4

Why is Complex I a major source of reactive oxygen species in mitochondria?

Accepted Answer

Complex I generates superoxide radicals during the large electron flow in oxidative phosphorylation. In healthy cells, ROS production is regulated at moderate levels necessary for normal cellular signaling. However, cancer cells with altered redox environments maintain elevated ROS production that triggers pro-tumorigenic pathways while exceeding normal antioxidant capacity.

Question 5

How do mutations in Complex II relate to human disease?

Accepted Answer

Although rare, mutations in Complex II can lead to tumors of the carotid body, a sensory organ in the peripheral nervous system. Additionally, defects in Complex II have been linked to Huntington's disease. These mutations disrupt normal electron transport and cellular energy production, contributing to disease pathology.

Question 6

What is the relationship between Complex I dysfunction and neurodegenerative disease?

Accepted Answer

In Parkinson's disease, there is a lack of function of Complex I, disrupting normal electron transport and ATP production in neurons. This mitochondrial dysfunction contributes to neurodegeneration. Complex I inhibitors like metformin can also induce programmed cell death in cancer cells by blocking respiratory functions.

Question 7

How do ETC inhibitors affect cancer cells differently than normal cells?

Accepted Answer

ETC inhibitors like metformin, resveratrol, and fenretinide disrupt electron flow and trigger elevated ROS production. Cancer cells, with their altered redox environment and high antioxidant capacity, become more sensitive to ROS level alterations than normal cells. When ROS exceeds their scavenging capacity, cancer cells undergo programmed cell death.

سلسلة نقل الإلكترون: المركب الأول (I) والثاني (II)